<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810600</url>
  </required_header>
  <id_info>
    <org_study_id>Gallium DOTATATE/PET scan</org_study_id>
    <nct_id>NCT02810600</nct_id>
  </id_info>
  <brief_title>Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors</brief_title>
  <acronym>PET/Ga68</acronym>
  <official_title>Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE&#xD;
      injection in patients with suspected or diagnosed with tumors expressing somatostatin&#xD;
      receptors. Each included patient will receive an administered dose of 50 mcg or less of the&#xD;
      peptide (DOTA-TATE) and a range of activity between 100 - 200 MBq of 68Ga-DOTA-TATE.&#xD;
&#xD;
      The efficacy of 68Ga-DOTA-TATE in assessing this kind of tumors has been proved by numerous&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Actual">May 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Record all adverse events</measure>
    <time_frame>June 2016-June 2018</time_frame>
  </primary_outcome>
  <enrollment type="Actual">2120</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gallium-68 DOTA TATE PET scan</intervention_name>
    <description>One PET/CT scan using Gallium-68 DOTA TATE</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected or diagnosed with tumors expressing somatostatin receptors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with suspected or proven tumors expressing Somatostatin receptors&#xD;
&#xD;
          2. Informed consent by patient (or parents if patient is less than 18 years of age)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (confirmed). In the case of a diagnostic procedure in a patient who is or&#xD;
             may be pregnant, a clinical decision is necessary considering the benefits against the&#xD;
             possible harm of carrying out any procedure.&#xD;
&#xD;
          2. Patient refusal to participate.&#xD;
&#xD;
          3. Impossibility to tolerate a decubitus position for 25 minutes&#xD;
&#xD;
          4. Prior allergic reaction to DOTA-TATE or somatostatin analogs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

